Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024040 | 1.00 | ALDH1A1 (0.40) | ALDH1A1TDP1CYP2C9TSHRMGAM | |
| SCHEMBL10024027 | 0.89 | ALDH1A1 (0.36) | ALDH1A1TDP1CYP2C9TSHRMGAM | |
| SCHEMBL1772274 | 0.83 | — | — | |
| SCHEMBL10024039 | 0.83 | MGAM (0.38) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL10024033 | 0.81 | ALDH1A1 (0.33) | ALDH1A1TDP1CYP2C9TSHR | |
| SCHEMBL10024038 | 0.81 | ALDH1A1 (0.33) | ALDH1A1TDP1CYP2C9TSHR | |
| SCHEMBL14520412 | 0.81 | MMP12 (0.42) | ALDH1A1TDP1CYP2C9TSHR | |
| SCHEMBL4630523 | 0.81 | MMP12 (0.42) | ALDH1A1TDP1CYP2C9TSHR | |
| SCHEMBL14633169 | 0.79 | L3MBTL1 (0.32) | ALDH1A1 | |
| SCHEMBL31571289 | 0.79 | TSHR (0.40) | ALDH1A1TSHRMGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150056181-A1 | NANOCARRIERS WITH MULTI-PHOTON RESPONSE ELEMENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | disclosed |
| EP-0916664-A1 | Enynes used in the synthesis of antifungal agents | Glaxo Wellcome, S.A. (ES) | 1999-05-19 | — | — | EP | disclosed |
| EP-0570197-B1 | Hydroxylamine derivatives | ZENECA LTD (GB) | 1995-12-13 | — | — | EP | disclosed |
| WO-1995030668-A1 | CYCLIC ETHER DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | ZENECA LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| US-5453439-A | Antiinflammatory agent, antiallergen; lipoxygenase inhibitor | ZENECA LIMITED (GB) | 1995-09-26 | — | — | US | disclosed |
| US-5334614-A | Lipoxygenase inhibitor | ZENECA LTD. (GB) | 1994-08-02 | — | — | US | disclosed |
| EP-0570197-A1 | Hydroxylamine derivatives | ZENECA LIMITED (GB) | 1993-11-18 | — | — | EP | disclosed |
| EP-0555067-A1 | Hydroxylamine derivatives as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056181-A1 | NANOCARRIERS WITH MULTI-PHOTON RESPONSE ELEMENTS | LRBA, PICALM, IPMK | ALDH1A1 4769/4885TDP1 476/4885CYP2C9 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.